Prostate cancer Drug's journey through bone tracked in new study
NCT ID NCT04521361
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 27 times
Summary
This study looked at how the drug radium-223 moves through bones in men with prostate cancer that has spread to the bones. Researchers wanted to see how much of the drug goes to healthy bone versus tumor areas. The study involved 46 men who received up to 6 injections of radium-223 and had scans to track the drug. The goal was to learn more about the drug's distribution, not to treat the cancer directly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BONE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Azienda USL IRCCS di Reggio Emilia_Arcispedale Santa Maria Nuova - S.C. Oncologia Provinciale
Reggio Emilia, Emilia-Romagna, 42123, Italy
-
Guy's and St. Thomas' NHS Trust, St. Thomas' Hospital
London, SE1 7EH, United Kingdom
-
HCL - Centre Hospitalier Lyon Sud
Pierre-Bénite, 69495, France
-
ICM - Institut du Cancer de Montpellier - Val d'Aurelle
Montpellier, 34298, France
-
Institut Claudius Regaud - iUCT Oncopole
Toulouse, 31059, France
-
Institut de Cancerologie Ouest - Saint-Herblain
Saint-Herblain, 44800, France
-
National Cancer Institute
Vilnius, LT-08660, Lithuania
-
Rambam Health Corporation
Haifa, 3109601, Israel
-
Royal Marsden NHS Trust (Surrey)
Sutton, Surrey, SM2 5PT, United Kingdom
-
Uniklinikum Salzburg - Landeskrankenhaus
Salzburg, 5020, Austria
-
University College London Hospitals NHS Foundation Trust
London, NW1 2PG, United Kingdom
-
Vilnius University Hospital Santaros Klinikos
Vilnius, LT-08661, Lithuania
Conditions
Explore the condition pages connected to this study.